Monday, August 29, 2016 6:42:39 AM
REUTERS 5:36 AM ET 8/29/2016
Aug 29 (Reuters) - Cynapsus Receives FDA fast track designation for apl
* 130277 for the treatment of off episodes in patients with Parkinson's disease
* Cynapsus receives FDA fast track designation for APL-130277 for the treatment of off episodes in patients with Parkinson's disease
* Says we plan to submit a new drug application (NDA) to FDA in first half of 2017
* Post dose titration phase, top line data for phase 3 efficacy trial CTH-300 is expected in mid-to-late Q4 of 2016
* CTH-201 phase 2 thorough QT study, is expected to commence in Q4 of 2016, and is planned to be completed in first half of 2017 Source text for Eikon: Further company coverage:
(c) Copyright Thomson Reuters 2016. Click For Restrictions - about.reuters.com/fulllegal.asp
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM